Flint Andrew W J, Brady Karina, Wood Erica M, Thao Le Thi Phuong, Hammond Naomi, Knowles Serena, Nangla Conrad, Reade Michael C, McQuilten Zoe K
Transfusion Research Unit, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
The Australian and New Zealand Intensive Care Research Centre (ANZIC-RC), School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
Crit Care Resusc. 2023 Dec 14;25(4):193-200. doi: 10.1016/j.ccrj.2023.10.006. eCollection 2023 Dec.
To describe current transfusion practices in intensive care units (ICUs) in Australia and New Zealand, compare them against national guidelines, and describe how viscoelastic haemostatic assays (VHAs) are used in guiding transfusion decisions.
Prospective, multicentre, binational point-prevalence study. All adult patients admitted to participating ICUs on a single day in 2021.
Transfusion types, amounts, clinical reasons, and triggers; use of anti-platelet medications, anti-coagulation, and VHA.
Of 712 adult patients in 51 ICUs, 71 (10%) patients received a transfusion during the 24hr period of observation. Compared to patients not transfused, these patients had higher Acute Physiology and Chronic Health Evaluation II scores (19 versus 17, = 0.02), a greater proportion were mechanically ventilated (49.3% versus 37.3%, < 0.05), and more had systemic inflammatory response syndrome (70.4% versus 51.3%, < 0.01). Overall, 63 (8.8%) patients received red blood cell (RBC) transfusions, 10 (1.4%) patients received platelet transfusions, 6 (0.8%) patients received fresh frozen plasma (FFP), and 5 (0.7%) patients received cryoprecipitate. VHA was available in 42 (82.4%) sites but only used in 6.6% of transfusion episodes when available. Alignment with guidelines was found for 98.6% of RBC transfusions, but only 61.6% for platelet, 28.6% for FFP, and 20% for cryoprecipitate transfusions.
Non-RBC transfusion decisions are often not aligned with guidelines and VHA is commonly available but rarely used to guide transfusions. Better evidence to guide transfusions in ICUs is needed.
描述澳大利亚和新西兰重症监护病房(ICU)当前的输血实践,将其与国家指南进行比较,并描述黏弹性止血检测(VHA)如何用于指导输血决策。
设计、设置和参与者:前瞻性、多中心、双边现患率研究。纳入2021年某一天入住参与研究的ICU的所有成年患者。
输血类型、输血量、临床原因和触发因素;抗血小板药物、抗凝药物和VHA的使用情况。
在51个ICU的712例成年患者中,71例(10%)患者在24小时观察期内接受了输血。与未输血的患者相比,这些患者的急性生理与慢性健康状况评分II更高(19分对17分,P = 0.02),机械通气的比例更高(49.3%对37.3%,P < 0.05),发生全身炎症反应综合征的比例更多(70.4%对51.3%,P < 0.01)。总体而言,63例(8.8%)患者接受了红细胞(RBC)输血,10例(1.4%)患者接受了血小板输血,6例(0.8%)患者接受了新鲜冰冻血浆(FFP),5例(0.7%)患者接受了冷沉淀。42个(82.4%)地点可进行VHA检测,但在可进行检测时,仅6.6%的输血事件使用了该检测。98.6%的RBC输血符合指南,但血小板输血仅61.6%符合,FFP输血为28.6%,冷沉淀输血为20%。
非RBC输血决策通常不符合指南,VHA检测普遍可用,但很少用于指导输血。需要更好的证据来指导ICU的输血。